Bentsen's health stocks
Executive SummaryDemocratic vice presidential candidate Lloyd Bentsen's financial disclosure statement, filed Aug. 15, lists assets and income from over a dozen drug and health care industry stocks, including income from Merck stock of between $ 15,000 and $ 50,000, the largest income contributor. The senator's most recent transactions in the drug industry, made within a month of the filing, were purchases of Johnson & Johnson and Schering common valued at $ 5,000-$ 15,000 and $ 5,000-$ 50,000, respectively. total value of Bentsen's income and asserts from drug and health care issues is at least $ 60,000. Because reporting rules require candidates only to list their holdings by value categories, the value of the senator's drug industry holdings could be well over $ 200,000. Among Bentsen's other drug issues are: Abbott, Lilly, Baxter, Squibb, and McKesson
You may also be interested in...
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.